Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by mmarquison Jun 15, 2011 10:44pm
329 Views
Post# 18721760

RE: good read

RE: good readBaylor,

Thanks for posting your find. It seems a quite comprehensive report. It will be worthwhile to study to discover what's happening currently in the stem cell field.
 
My quick scan/read indicates that it focuses on naturally Occuring Stem Cells and the issues and research related to that area; it does not, however, touch on the non-stemcell approach that SSS is taking (nor does it make any reference to the work or any recognition that SSS exists). Too bad we didn't get a mention as an alternative approach, that would have been encouraging.

M
Bullboard Posts